NYSE:RCUSBiotechs
Assessing Arcus Biosciences’ Valuation After Halting Key GI Trials and Pivoting to Casdatifan-Focused Strategy
Arcus Biosciences, Inc., has drawn fresh attention after scrapping its late stage STAR-221 and EDGE-Gastric trials in upper gastrointestinal cancers, a setback that also clarifies where the next wave of potential value may come from.
See our latest analysis for Arcus Biosciences.
The abrupt end to STAR-221 and EDGE-Gastric triggered a sharp reset in sentiment, with a 1 day share price return of minus 14.36 percent. Arcus still posts an 85.92 percent 3 month share price return and a 33.89...